Finance entity
markets is the sole category represented across all 1 tracked stories. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. The 6 average consequence score is below the beat benchmark of 6.2 in the same window. orforglipron appears in 1 tracked Finance story from March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 74 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering orforglipron. Shared-story counts are live from our verified record — not editorial picks.
As equity markets navigate 2026 volatility, analysts are highlighting a mix of established healthcare leaders and emerging AI infrastructure plays as top growth opportunities. Eli Lilly’s dominance in the obesity market and Nebius’s projected $7 billion revenue surge represent the diverse strategies for capturing alpha in the current cycle.
orforglipron is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
